| Analysis | Metabolite Name | Measured Value | Units | Model | Intervention |
|---|---|---|---|---|---|
| Reversed phase UNSPECIFIED ION MODE | Etiocholan-3α-ol-17-one glucuronide | 0.0000036 | peak area | Wild type | B. breve MCC1274 |
| Reversed phase UNSPECIFIED ION MODE | Etiocholan-3α-ol-17-one glucuronide | 0.0000049 | peak area | Alzheimer’s disease model | Saline |
| Reversed phase UNSPECIFIED ION MODE | Etiocholan-3α-ol-17-one glucuronide | 0.0000069 | peak area | Alzheimer’s disease model | Saline |
| Reversed phase UNSPECIFIED ION MODE | Etiocholan-3α-ol-17-one glucuronide | peak area | Alzheimer’s disease model | B. breve MCC1274 | |
| Reversed phase UNSPECIFIED ION MODE | Etiocholan-3α-ol-17-one glucuronide | peak area | Alzheimer’s disease model | Saline | |
| Reversed phase UNSPECIFIED ION MODE | Etiocholan-3α-ol-17-one glucuronide | peak area | Wild type | B. breve MCC1274 | |
| Reversed phase UNSPECIFIED ION MODE | Etiocholan-3α-ol-17-one glucuronide | peak area | Wild type | Saline |
- UCSD Metabolomics Workbench, a resource sponsored by the Common Fund of the National Institutes of Health
|